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Background. There are considerable numbers of patients coinfected with human immunodeﬁciency virus
(HIV) and visceral leishmaniasis (VL) in the VL-endemic areas of Bihar, India. These patients are at higher
risk of relapse and death, but there are still no evidence-based guidelines on how to treat them. In this study, we
report on treatment outcomes of coinfected patients up to 18 months following treatment with a combination
regimen.
Methods. This retrospective analysis included all patients with conﬁrmed HIV-VL coinfection receiving com-
bination treatment for VL at a Médecins Sans Frontières treatment center between July 2012 and September 2014.
Patients were treated with 30 mg/kg body weight intravenous liposomal amphotericin B (AmBisome) divided as 6
equal dose infusions combined with 14 days of 100 mg/day oral miltefosine (Impavido). All patients were encour-
aged to start or continue on antiretroviral therapy (ART).
Results. 102 patients (76% males, 57% with known HIV infection, 54% with a prior episode of VL) were fol-
lowed-up for a median of 11 months (interquartile range: 4–18). Cumulative incidence of all-cause mortality and VL
relapse at 6, 12, and 18 months was 11.7%, 14.5%, 16.6% and 2.5%, 6.0%,13.9%, respectively. Cumulative incidence of
poor outcome at 6, 12, and 18 months was 13.9%, 18.4%, and 27.2%, respectively. Not initiating ART and concurrent
tuberculosis were independent risk factors for mortality, whereas no factors were associated with relapse.
Conclusions. In this Bihar-based study, combination therapy appeared to be well tolerated, safe, and effective
and may be considered as an option for treatment of VL in HIV coinfected patients.
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Visceral leishmaniasis (VL; Kala-azar) is a vector-borne
disease caused by Leishmania donovani parasites. VL is
endemic in the Indian state of Bihar, which accounts for
40% of the worldwide burden of VL [1]. Although the
prevalence of human immunodeﬁciency virus (HIV) in
Bihar is considered low (0.2%–0.3%), it is one of the
few states where prevalence is increasing [2]. A recent
study from India has suggested that 2.4% of all patients
≥14 years of age presenting with VL were unknowingly
coinfected with HIV [3].
HIV-infected patients are more likely to develop
symptomatic VL due to reactivation of dormant Leish-
mania infection acquired prior to being infected with
HIV or due to a much higher rate of clinical manifesta-
tion following primary Leishmania infection after
acquiring HIV. Therefore, VL is generally considered
an opportunistic infection in patients with HIV and
often presents with atypical clinical features [4].
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Coinfected patients are at higher risk of relapse and death, and
this risk appears inversely correlated with CD4 counts. Further-
more, VL adversely affects the response to antiretroviral treat-
ment [4, 5]. Worse outcomes and the treatment challenges
faced by coinfected patients as compared to immunocompetent
patients are well documented in the literature [6].
There are currently no evidence-based treatment recommenda-
tions for coinfected patients in Asia. Moreover, observational
studies by Médecins Sans Frontières (MSF) in India have shown
that outcomes for HIV coinfected patients receiving 20 mg/kg
AmBisome (Gilead Pharmaceuticals, Foster City, California)
were substantially worse than in VL patients not known to be
HIV coinfected [7–9],whereas a recent study in Ethiopia showed
that 32% of coinfected patients demonstrated parasitological fail-
ure following treatment with 30 mg/kg AmBisome despite clini-
cal improvement [10].Therefore, theMSF VL treatment program
in Bihar, in collaboration with the Rajendra Memorial Research
Institute (RMRI), chose to treat HIV-VL coinfected patients on a
compassionate basis using a combination of 30 mg/kg AmBi-
some and 14 days of miltefosine (Impavido, Paladin, Canada).
This combination was adopted after consultation of experts, tak-
ing into account the synergistic properties of AmBisome andmil-
tefosine [6, 11] and has been used in another center with
promising results [12]. Additionally, the compassionate use of
miltefosine in combination with liposomal amphotericin B (at
30 mg/kg total dose) in 111 HIV coinfected VL patients in east
Africa seems to suggest substantially higher cure rates and lower
failure rates both in primary VL and VL relapse than high-dose
AmBisome monotherapy[12]. In this report, we describe the out-
comes up to 18 months following treatment with this combina-
tion therapy under routine program conditions in Bihar, India.
METHODS
We did a retrospective analysis of a clinical cohort of coinfected
patients using data collected routinely during MSF’s VL care
programme activities in Bihar. In August 2013, MSF participat-
ed in a pilot study to produce evidence on the ﬁeld safety and
effectiveness of new lower dose treatment modalities recom-
mended by the World Health Organization (WHO) [9] to
treat VL in Bihar (CTRI/2012/08/002891). Patients with HIV/
VL coinfection were excluded from the study as these treat-
ments are not recommended for this group [5]; however, their
data were recorded in the trial surveillance register and as sug-
gested in the pilot study protocol were treated on a compassion-
ate basis with a combination regimen of AmBisome and
miltefosine (Figure 1).
Visceral Leishmaniasis and HIV Diagnosis
Diagnosis of VL involved a clinical case deﬁnition (fever >2
weeks and splenomegaly), which was conﬁrmed using the rK39
rapid diagnostic test (DiaMed-IT-Leish). For immunocompetent
patients in India it is 98.8% and 97.6% sensitive and speciﬁc re-
spectively [13]; its accuracy in immunocompromised patients
had not yet been fully established although is likely to be lower.
In cases of suspected relapse, or where there was high suspicion
despite negative antibody detection tests, conﬁrmation by splenic
or bone marrow aspiration was performed.
All patients diagnosed with VL (both primary and relapses)
were offered patient initiated counselling and testing (PICT) for
HIV regardless of known HIV status. HIV testing was per-
formed using the Determine-HIV 1/2 rapid diagnostic test,
and positive patients were referred to the Ministry of Health
HIV testing facility within the same hospital for conﬁrmation
using two to three further testing kits as per National AIDS
Control Organization (NACO) guidelines [14]. Any discordant
tests were conﬁrmed using Western Blot.
Visceral Leishmaniasis Treatment Protocol
Patients with HIV-VL coinfection were treated as in-patients
using a combination of 30 mg/kg body weight AmBisome di-
vided in 6 equal dose infusions given on alternate days, concur-
rently with 14 days of oral miltefosine. The dose of miltefosine
was calculated according to patient weight (≥25 kg 50 mg twice
daily; Weight 12–<25 kg, 50 mg once daily). Test of cure was
not routinely performed, with patients discharged as “initial
cures” once they completed a full course of VL treatment and
showed clinical improvement, cessation of fever, reduction of
Figure 1. Flow chart of analysis of 102 human immunodeﬁciency virus
visceral leishmaniasis (HIV-VL) coinfected patients, Bihar India.
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spleen size, and return of appetite at the time of discharge as per
WHO descriptions of treatment response [15].
All newly diagnosed HIV patients were advised and coun-
selled to start ART at the nearest government ART centre as
per NACO guidelines [14]. Of note, unlike in the African sub-
continent, typical VL in India is not yet considered a stage IV
AIDS-deﬁning opportunistic infection; hence ART initiation is
not typically offered to all HIV patients with VL regardless of
CD4-count [16].
Patient Follow-up
At the time of discharge, all patients were instructed to return to
the treatment centre if experiencing symptoms of relapse. Rou-
tine follow-up visits for all patients were scheduled every month
to coincide with collection of ART from the ART centre. Fol-
low-up absentees were actively traced. During each follow-up,
patients were clinically screened by a physician for signs of re-
lapse, and parasitological conﬁrmation performed in case of
suspicion. CD4 counts and ART adherence information were
collected, and communication with ART providers maintained
to allow integrated longer-term management of patients.
Data Collection and Analysis
As with all patients treated in the MSF program, sociodemo-
graphic characteristics, clinical, anthropometric, laboratory data,
and data on adverse events were routinely recorded on patient
treatment cards and entered in an electronic database by trained
data entry encoders. In the case of co-infected patients, CD4
counts and ART status were also routinely recorded, and the pro-
gram epidemiologist performed double data entry prior to the ret-
rospective analysis. The primary endpoint for analysis was
relapse-free survival during follow-up after the start of treatment.
For each patient, person-time at risk was calculated from the date
of treatment initiation to the date of the “death,” “ﬁrst relapse,”
“poor outcome” (deﬁned as either relapse or death), “lost to fol-
low-up” (deﬁned as not attending follow-up visit after discharge),
or the date of last visit. All data were censored on 31 November
2014. Cumulative incidence of outcome was then estimated using
the Kaplan–Meier method. Comparisons between groups were
performed using the log-rank test. For risk factor analysis multi-
variable Cox proportional hazards modeling was performed. All
variables associated with the outcome at the P < .05 signiﬁcance
level in bivariate analysis were considered in a forward step-wise
multivariable model, with a signiﬁcance level of P < .05 used to
retain variables in the ﬁnal model. All data analyses were conduct-
ed using SPSS version 21 statistical software (IBM Chicago,
Illinois).
Ethics Consideration
This retrospective analysis of clinical cohort data was approved
by the Ethics Advisory Group of the International Union
Against Tuberculosis and Lung Disease and met the criteria
of MSF’s International Ethics Review Committee for a study in-
volving the analysis of routinely collected program data. The
compassionate use of the combination regimen for coinfected
patients was approved ex-ante (on the basis of protocol CTRI/
2012/08/002891) by the MSF International Ethics Review Com-
mittee and the Institutional Ethics Review Board of RMRI,
Patna. All patients were invited to give informed consent
prior to HIV testing, and all electronic data were analysed
anonymously.
RESULTS
Baseline and Clinical Characteristics
A total of 102 HIV-VL coinfected patients initiated treatment
with AmBisome and miltefosine combination therapy during
the study period. The median length of follow-up was 11 (inter-
quartile range [IQR]: 4–18) months following VL treatment ini-
tiation. The majority (76%) was male. Over half (57%) of patients
reported being aware they were HIV positive at the time of VL
diagnosis; the remainder were diagnosed with HIV at the same
time as VL diagnosis. A total of 39 (38%) cases were diagnosed
with VL on the basis of clinical criteria and rk39 rapid diagnostic
test alone, whereas 63 (61.8%) patients had either splenic or bone
marrow biopsy for additional parasitological conﬁrmation. Base-
line CD4-counts were available for 73 patients with a median
CD4 count of 169 (IQR: 88–230) cells/µL. Of these, 67% had
CD4-count <200 cells/µL. All but 8 of the cohort received ART
treatment; of those who did not, half died within 4 months of
completing treatment for VL. Of those receiving ART, 52
(51%) were already established on ART at the time of initiating
VL treatment; the remainder started after completion of VL treat-
ment. Baseline and clinical characteristics of patients are summa-
rized in Table 1 and laboratory parameters are shown in Table 2.
Treatment Outcomes
The combination treatment was well tolerated by the majority
of patients with minor adverse events recorded among 7 pa-
tients; 5 patients reported nausea and vomiting, 1 patient devel-
oped back pain, and 1 patient had rigors. Two patients died
after being referred to nearby specialist centers for complica-
tions related to HIV before completion of treatment; 1 died
from sepsis secondary to a large scrotal abscess whereas the
other died from bacterial meningitis. Completion of treatment
was associated with a signiﬁcant decrease in spleen and liver size
at time of discharge from the hospital; however, no signiﬁcant
changes in haemoglobin level or body weight were observed by
completion of treatment. Kidney and liver function tests were
performed after treatment completion on a limited number of
patients suspected to have complications; changes in mean val-
ues of these tests are shown in Table 3.
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Sixteen (15.7%) deaths were identiﬁed during the follow-up
period. Two patients died before completion of treatment,
whereas 4 others died within 2 months following treatment
completion. Median time to death was 3.3 months (IQR: 1.3–
6.5). Cumulative incidence of mortality at 6, 12, and 18 months
was 11.7%, 14.5%, and 16.6%, respectively (Supplementary Fig-
ure 1). Among the patients discharged as initial cure, eight cases
of VL relapse were identiﬁed during follow-up with a median
time to relapse of 11 (IQR: 4–15) months. The estimated risk
of relapse was 2.5%, 6.0% and 13.9% at 6, 12 and 18 months re-
spectively. In terms of overall VL treatment response, the esti-
mated cumulative incidence of poor outcomes by 6, 12, and 18
months were 13.9%, 18.4%, and 27.2%, respectively. One patient
Table 1. Baseline Characteristics of Patients With Visceral
Leishmaniasis and Human Immunodeﬁciency Virus Coinfection
Variable N % Median (IQR)
Sex
Male 77 75.5
Female 25 24.5
Age group (years) 36 (30,45)
<15 2 2.0
15–29 13 12.7
30–44 58 56.9
45–59 23 22.5
≥60 6 5.9
Time from symptoms onset to diagnosis 8 (4,12)
>4 wk 64 62.7
≤4 wk 38 37.3
History of previous treatment for VL 1 (0,1)
Second or more relapse 13 12.7
First relapse 42 41.2
Primary episode 47 46.1
VL drug used previously
None 47 46.1
AmBisome (20 mg/kg body weight) 18 17.6
Miltefosine 12 11.8
Amphotericin B 11 10.8
Sodium stibogluconate (SSG) 8 7.8
Fungisome 2 2.0
AmBisome (5 mg/kg bodyweight) and
Miltefosine combination
1 1.0
Drug unknown 3 2.9
Spleen size, (in cm) 8 (6,10)
>6 60 58.8
3–6 36 35.3
<3 6 5.9
Liver size, (in cm) 2 (0,4)
>3 30 29.4
1-3 33 32.4
0 39 38.2
Body mass index (kg/m2) 17.4 (15.8,18.7)
<16 29 28.4
≥16 73 71.6
Concurrent tuberculosis diagnosis
Positive 9 8.8
Negative 93 91.2
HIV status at time of treatment for VL
Previously diagnosed as HIV positive 58 56.9
Diagnose HIV positive at time of VL
treatment
44 43.1
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range;
VL, visceral leishmaniasis.
Table 2. Baseline Laboratory Parameters of Patients With Visceral
Leishmaniasis and Human Immunodeﬁciency Virus Coinfection
Variable N % Median (IQR)
Hemoglobin (g/dL) (n = 102) 8.2 (6.4,9.7)
<6 16 15.7
6–7 32 31.4
>8 54 52.9
Potassium (mEq/L) (n = 65) 3.9 (3.5,4.2)
2.5 to <3 1 1.5
3 to <3.5 15 23.1
≥3.5 49 75.4
Creatinine mg/dL (n = 97)
<1.2 81 83.5
1.2–2 11 11.3
>2 5 5.2
SGPT U/L (n = 92) 26.3 (17.1,39.3)
<48 77 41.3
>48–200 14 56.5
>200 1 2.2
SGOT U/L (n-92) 51 (35.3,66.7)
<46 38 41.3
>46–200 52 56.5
>200 2 2.2
Bilirubin (mg/dL) (n = 68)
≥1.9 1 1.5
0.5–1.9 28 41.2
<0.5 39 57.4
Platelets count cells/µL
(n = 89)
146 000 (109 500, 202 500)
<150 000 46 51.7
≥150 000 43 48.3
Baseline CD4 count, cells/
µL (n = 73)a
169 (88.5,230.5)
<100 22 30.1
100 to <200 27 37.0
200 to <350 16 21.9
≥350 8 11.0
Abbreviations: IQR, interquartile range; SGOT, serum glutamic oxaloacetic
transaminase; SGPT, serum glutamate-pyruvate transaminase; VL, visceral
leishmaniasis.
a Window of 3 months prior to VL treatment until 3 months after.
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was diagnosed with macular lesions suggestive of PKDL 13
months after completing VL treatment.
Predictors for Death, Relapse and Poor Outcome
No demographic or clinical characteristics were signiﬁcantly as-
sociated with relapse in bivariate analysis, even though a diag-
nosis with tuberculosis (Supplementary Table 1) showed a
strong association (hazard ratio [HR]: 9.5; 95% conﬁdence in-
terval [CI], .9–97.9; P = .06). Concurrent tuberculosis, haemo-
globin ≤6 g/dL, baseline CD4-count <100 cell/µL, and lack of
ART initiation were identiﬁed as risk factors for mortality in bi-
variate analysis. However, only infection with tuberculosis (ad-
jacent HR [aHR]: 5.3; 95% CI, 1.6–17.8; P < .01) and ART
initiation status maintained statistical signiﬁcance through the
forward step-wise approach and were therefore retained in the
ﬁnal multivariable model for mortality (Table 4). Of the 102 pa-
tients presenting, 73 had documented CD4 counts at the time of
treatment; for the purposes of multivariable modeling multiple
imputation was used to complete the data set; however, this had
minimal impact on the model output [17].
In the ﬁnal multivariable model, failure to start ART was
an independent risk factor for mortality compared to those
who started ART prior to VL treatment (aHR: 8.0; 95% CI,
2.0–32.5; P < .01). ART initiation following VL treatment was
similarly associated with higher mortality than those already
established on ART, but did not reach statistical signiﬁcance
(aHR: 2.8; 95% CI, .8–9.5; P = .101).
In terms of overall poor outcome, only concurrent tuberculo-
sis (aHR: 7.5; 95% CI, 2.5–22.1; P < .01) was retained as an in-
dependent risk factor (Supplementary Table 2).
DISCUSSION
This is the ﬁrst report to our knowledge on HIV-VL coinfected
patients receiving treatment with a combination of AmBisome
and miltefosine therapy in the Indian subcontinent. Our data
suggest that combination therapy is a well-tolerated and
effective treatment regimen for an episode of VL in HIV-VL co-
infection within the Indian setting. The choice of 14 days of
concurrent oral treatment had the added beneﬁt of ensuring
compliance as both treatments can be administered during
the inpatient stay. However, a high risk of relapse and early
death, similar to earlier studies on short- and long-term out-
comes of coinfected patients is described in this cohort, partic-
ularly among tuberculosis patients and those not initiated on
antiretroviral treatment. When compared to patients with VL
not known to be HIV-infected treated with a lower dose mono-
therapy of 20 mg/kg AmBisome in the same setting [7], the out-
come among coinfected patients observed in our study was
considerably worse—mortality and relapse rates at 12 months
for patients were 0.9% and 3.7% compared to 14.5% and
6.0%, respectively, for the coinfected patients described here.
In HIV-VL coinfected patients already taking or initiated on
ART, this study demonstrated slightly higher overall mortality
but substantially reduced relapse rates compared to coinfected
patients treated with a lower dose 20–25 mg/kg AmBisome
monotherapy, with mortality and relapse rates at 12 months of
11.2% and 6.4% compared to 8.7% and 16.2%, respectively [8].
Concurrent tuberculosis was found to be an independent risk fac-
tor for overall poor outcome in our multivariable model, similar
to other studies [8, 9]. No other sociodemographic or clinical fac-
tors were found to be associated with poor outcomes.
Baseline CD4 counts at the time of VL diagnosis were low in
our cohort, with counts <100 cells/µL at baseline being a signiﬁ-
cant risk factor for mortality in bivariate analysis, consistent with
reports from an Ethiopian coinfected cohort [18].Patients receiv-
ing ART had substantially lower mortality than those who did
not, conﬁrming results of earlier studies on coinfected patients
in the same programme [8, 9] and reinforcing the need for the
central place of ART in the management of this group of patients.
Considering relapse, no associations with demographic char-
acteristics were found, which is in keeping with a systematic re-
view describing predictors of VL relapse in HIV-infected
patients [19]. However, unlike this review, our study failed to
Table 3. Clinical and Laboratory Parameters Before and After Treatment (Assessed ≥day 14) With Combination Therapy
Variable Before Treatment Mean (SD) End of Treatment Mean (SD) Within Patient Difference P Value
Weight, kg (n = 100) 44.3 (8.8) 44.6 (8.7) 0.3 (−0.1, 0.6) .15
Spleen size, cm (n = 101) 8.2 (4.1) 4.1 (3.9) −4.1 (−4.7, −3.6) <.001
Liver size, cm (n = 101) 2.2 (2.3) 0.8 (1.4) −1.4 (−1.9,−0.9) <.001
Hemoglobin, g/dL (n = 93) 8.2 (2.1) 8.1 (1.8) −0.2 (−0.4,0.1) .27
Potassium (n = 17) 3.7 (0.6) 4.3 (0.7) 0.5 (0.2, 0.9) .003
SGPT, U/L (n = 18) 37.8 (33.0) 29.2 (17.2) −8.6 (−26.1,8.9) .31
SGOT, U/L (n = 17) 61.9 (56.3) 52.8 (43.9) −9.1 (−46.1,27.9) .61
Platelets cells/L (n = 12) 156 667 (77 713) 222 250 (115 180) 65 583 (30 868 100 299) .002
Abbreviations: SD, standard deviation; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamate-pyruvate transaminase.
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establish low CD4 count and previous history of VL treatment
as risk factors for relapse, possibly for lack of power.
This study has several limitations. Being a retrospective anal-
ysis of program data, and despite demographic and clinical data
related to VL treatment being complete, some important HIV-
related data were missing, particularly timely CD4 counts fol-
lowing diagnosis. Second, all-cause mortality was used in the
analysis, and as such we were not able to ascertain documented
causes of deaths discovered during follow-up. However, all but 2
patients were discharged in good clinical condition following
treatment completion, and the 2 deaths occurring before com-
pletion of treatment were not considered related to the therapy.
Therefore, we believe it is unlikely that any of the 16 deaths re-
corded in the cohort was a treatment related serious adverse
event. The 2 patients who died after relapsing did so after re-
treatment was completed and were discharged with improved
clinical condition. Finally, test of cure was not routinely per-
formed on patients unless there was suggestion of treatment
failure clinically, of which there were none; therefore the
study may have underdiagnosed initial treatment failures.
Presently, the WHO recommends monotherapy with AmBi-
some up to a total of 40 mg/kg in divided doses for over a
month in HIV-VL coinfected patients worldwide; however,
this recommendation is made on the basis of patient case series
involving L. infantum in Europe alone [4]. To our knowledge,
no case of L. donovani infection in a patient with HIV treated
with this regimen has been documented in the Indian sub-
continent, whereas high dose monotherapy with AmBisome al-
ready appears to be ineffective in African L. donovani infection
[10], where studies evaluating the combination of AmBisome
and miltefosine in coinfected patients have already begun [20].
We therefore suggest that the use of this WHO-recommended
regimen and the combination described in this study need to be
investigated in further studies in order to help establish optimal
dosing and safety proﬁles to help determine the best manage-
ment of this challenging group of patients.
Table 4. Risk Factors Analysis for Mortality in Patients With Visceral Leishmaniasis-Human Immunodeﬁciency Virus Coinfection
Variable Death N (%) Survived N (%) Crude HR (95% CI) Crude P Value Adjusted HR (95% CI) Adjusted P Value
Sex
Female 6 (24.0) 19 (76.0) 1.7 (.6,4.8) .28
Male 10 (13.0) 67 (87.0)
Age (years)
>40 7 (17.1) 34 (82.9) 1.2 (.4,3.2) .74
≤40 9 (14.8) 52 (85.2)
Tuberculosis diagnosis
Positive 4 (44.4) 5 (55.6) 6.6 (2.0,22.0) .002 5.3 (1.6, 17.8) .008
Negative 12 (12.9) 81 (86.0)
History of previous VL treatment
Yes 7 (12.7) 48 (87.3) 0.6 (.2,1.6) .32
No 9 (19.1) 38 (87.1)
Spleen size (cm)
>8 6 (14.3) 36 (85.7) 0.8 (.3,2.2) .67
≤8 10 (16.7) 50 (83.3)
BMI (kg/m2)
<16 7 (24.1) 22 (75.9) 2.1 (.8,5.8) .13
≥16 9 (12.3) 64 (87.7)
Hemoglobin (g/dL)
≤ 6 6 (30.0) 14 (70) 2.9 (1.03,7.9) .04
>6 10 (12.2) 72 (87.8)
Baseline CD4 count (cells/µL)a
<100 8 (25) 23 (75) 2.0 (1.1,30.8) .04
≥100 8 (11.7) 62 (88.3)
ART initiation
Never started 4 (50.0) 4 (50.0) 9.1 (2.3,36.5) .002 8.0 (2.0,32.5) .004
After VL diagnosis 8 (19.0) 34 (81.0) 3.2 (0.95,10.7) .06 2.8 (.8,9.5) .101
Before VL diagnosis 4 (7.7) 48 (92.3)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; HR, hazard ratio; VL, visceral leishmaniasis.
a 73/102 baseline CD4 counts were available; the remainder were completed through multiple imputation.
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Considering the high probability of relapse in coinfected pa-
tients, there is a need to provide a safe and effective treatment
while protecting the limited drugs available from the develop-
ment of resistance. This is more pertinent because resistance
mechanisms to amphotericin B have recently been described
[21], and evidence from Ethiopia that high-dose AmBisome
monotherapy was much less effective in HIV-positive VL relapse
patients who had received previous treatment with AmBisome or
amphotericin B compared with those who had not [10].
Our ﬁndings have a number of implications for policy and
practice in India. Current WHO and NACO guidelines describe
“atypical disseminated VL” as a stage IV-deﬁning opportunistic
infection, rather than simply “visceral leishmaniasis” and there-
fore do not recommend initiation of ART in all HIV patients
with typical VL irrespective of CD4 count. This contrasts with
WHO expert committee on VL recommendations delivered in
2010, where typical VL infection in HIV-infected patients is
clearly identiﬁed as an AIDS-deﬁning illness. These inconsis-
tencies cause confusion in the ﬁeld when making decisions to
start ART in coinfected patients [16]. The outcomes of the re-
cent expert meeting between NACO and the NVBDCP in India
to develop guidelines for the management of HIV-VL coinfec-
tion [22] is a strong ﬁrst step in developing clearer recommen-
dations and convergence between WHO ART guidelines and
VL guidelines. In turn, these study results strengthen emerging
evidence that typical VL should be considered as a clear entry
criterion in the stage IV deﬁnition of HIV, support the need to
offer PICT to all patients diagnosed with VL and crucially that
extended follow-up of coinfected patients is required to ensure
relapses are detected early and treated appropriately. This needs
to be done using a coordinated multidisciplinary approach be-
tween VL and HIV/AIDS programs.
In conclusion, the administration of a combination therapy
of AmBisome and miltefosine appears safe and effective
among HIV-VL coinfected patients under programme condi-
tions in India. Early diagnosis of the coinfection, prompt initi-
ation of ART, and anti-leishmania therapy, screening and
treatment for tuberculosis and extended follow-up may lead
to more favorable treatment outcomes.
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